Oppenheimer reiterated its Outperform rating and $115.00 price target for Gilead Sciences (NASDAQ:GILD) stock, following a strong fourth-quarter performance that surpassed consensus estimates. Gilead ...

TD Cowen increased its price target on Gilead Sciences (NASDAQ:GILD) shares to $100 from the previous $95, while maintaining a Buy rating on the stock. The biotech giant, currently trading near its 52 ...

Gilead Sciences faces revenue growth challenges as its blockbuster drugs lose exclusivity by 2033. Check out my ...

During the Positive Nutrition Broadcast series, representatives from Zevia, Suja Organic, DSM-Firmenich and Euromonitor ...

Guardant Health is overcoming skepticism with new cancer tests. Learn why GH stock is a buy, with strong growth and a shift ...

DUBAI: Dubai’s Arab Health medical expo could be the medicine to the Pakistani pharmaceutical and surgical industry’s market ...

A medical director of liver transplants in Colorado says he has noticed a worrying rise in the number of young people in ...

Recent research suggests that a new approach could help even patients with advanced forms of fatty liver disease.

Gene editing is already being used to treat a handful of rare genetic diseases; however, most therapies involve breaking or ...

Researchers describe successful tumor removal through the use of immunotherapy and targeted radiation therapy (TARE), in a patient previously considered ineligible for the procedure.

A guardian molecule ensures that liver cells do not lose their identity. This has been discovered by researchers from the ...